key: cord-0892485-p3g24lzn
authors: Jolliffe, D. A.; Faustini, S. E.; Holt, H.; Perdek, N.; Maltby, S.; Talaei, M.; Greenig, M.; Vivaldi, G.; Tydeman, F.; Symons, J.; Davies, G. A.; Lyons, R.; Kee, F.; Sheikh, A.; Shaheen, S. O.; Richter, A.; Martineau, A. R.
title: Determinants of antibody responses to two doses of ChAdOx1 nCoV-19 or BNT162b2 and a subsequent booster dose of BNT162b2 or mRNA-1273: population-based cohort study (COVIDENCE UK)
date: 2022-02-15
journal: nan
DOI: 10.1101/2022.02.14.22270930
sha: e34c6c3675b2bcdbc937e7b0c84f3853a1d1b4c1
doc_id: 892485
cord_uid: p3g24lzn

Background: Antibody responses to SARS-CoV-2 vaccination vary for reasons that remain poorly understood. Methods: We tested for presence of combined IgG, IgA and IgM (IgGAM) anti-spike antibodies before and after administration of two doses of ChAdOx1 nCoV-19 (ChAdOx1, Oxford-AstraZeneca) or BNT162b2 (Pfizer-BioNTech) in UK adults participating in a population-based longitudinal study who received their first dose of vaccine from December 15, 2020 to July 10, 2021. Information on sixty-six potential sociodemographic, behavioural, clinical, pharmacological and nutritional determinants of serological response to vaccination was captured using serial online questionnaires. We used logistic regression to estimate multivariable-adjusted odds ratios (aORs) for associations between independent variables and risk of seronegativity following two vaccine doses. Participants who were seronegative after receiving two vaccine doses were offered an additional antibody test following subsequent administration of a booster dose of BNT162b2 or mRNA-1273 (Moderna) from September 23 to December 12, 2021. Findings: Serology results following two vaccine doses were available for 9,101 participants, of whom 5,770 (63.4%) received ChAdOx1 and 3,331 (36.6%) received BNT162b2. Anti-spike IgGAM was undetectable in 378 (4.2%) participants at a median of 8.6 weeks (IQR 6.4-10.7 weeks) after their second dose of vaccine. Seronegativity following two doses of SARS-CoV-2 vaccination was associated with administration of ChAdOx1 vs BNT162b2 (aOR 7.03, 95% CI 4.39-11.24), shorter interval between first and second vaccine doses (aOR 2.37, 1.06-5.26, for <6 weeks vs >10 weeks; aOR 1.59, 1.18-2.13, for 6-10 weeks vs >10 weeks), poorer self-assessed general health (aOR 3.33, 1.49-7.46, for poor vs excellent), immunodeficiencies (aOR 6.75, 2.63-17.35) and prescription of systemic immunosuppressants (aOR 3.76, 2.44-5.78). By contrast, pre-vaccination SARS-CoV-2 seropositivity (aOR 0.16, 0.04-0.70, for symptomatic seropositives vs seronegatives) and supplemental vitamin D intake (aOR 0.73, 0.53-0.99) were associated with reduced risk of post-vaccination seronegativity. 247/378 (65.3%) of participants who were seronegative after two doses of ChAdOx1 vs BNT162b2 provided a third sample at a median of 7.8 weeks (IQR 5.8-10.4) after receiving a booster dose of BNT162b2 or mRNA-1273: eight (3.2%) of them remained seronegative after three vaccine doses, all of whom either had a primary immunodeficiency or were taking systemic immunosuppressant drugs. Interpretation: We identify multiple determinants of antibody responses to two doses of ChAdOx1 or BNT162b2, many of which are potentially modifiable. Booster doses of BNT162b2 or mRNA-1273 were highly effective in achieving seroconversion in those who failed to mount antibody responses following two doses of ChAdOx1 or BNT162b2.

Vaccination against SARS-CoV-2 represents a key tool for COVID-19 control.

However, existing vaccines offer imperfect protection against disease, reflecting heterogeneity in immunogenicity. 1, 2 Improved understanding of factors influencing immune responses to SARS-CoV-2 vaccines could lead to discovery of effectmodifiers that could be harnessed to augment vaccine immunogenicity, and identify groups of poor responders who might benefit from more intensive vaccine dosing regimens or implementation of other protective measures. 3 Existing studies investigating determinants of vaccine immunogenicity have reported that lower antibody responses following SARS-CoV-2 vaccination associate with administration of viral vector vs messenger RNA (mRNA) vaccines, older age, poorer general health, immunosuppression and shorter inter-dose intervals. [4] [5] [6] [7] [8] [9] [10] [11] Higher postvaccination antibody titres are seen in those with evidence of SARS-CoV-2 infection before vaccination. 9, 12, 13 However, these studies are limited in several respects: many are conducted in specific populations such as health care workers 5, 9, 12, 13 or in individuals with a particular demographic or clinical characteristic that may influence vaccine immunogenicity, 6, 10, 11 which may constrain generalisability of their results.

Where population-based studies have been done, 4, 7, 8 these did not compare the effect of two doses of viral vector vs mRNA vaccines on host response; neither did they systematically ascertain participants' pre-vaccination SARS-CoV-2 serostatus, which is an important potential confounder of associations reported. Moreover, these studies did not investigate effects of modifiable factors that have been posited to influence responses to vaccination, such as time of day of inoculation, 14 nutrition, 15 sleep, 16 alcohol use, 17 tobacco smoking 18 and peri-vaccination use of anti-pyretic analgesics. 19 There is also a lack of population-based studies investigating responses to booster doses of SARS-CoV-2 vaccines in individuals who failed to mount an antibody response after their primary course of vaccination.

We sought to address these limitations by investigating a comprehensive range of potential sociodemographic, behavioural, clinical, pharmacological and nutritional determinants of antibody responses in a population-based cohort of UK adults (COVIDENCE UK) 20 following administration of two doses of either BNT162b2 (Pfizer-BioNTech) or ChAdOx1 nCoV-19 (Oxford-AstraZeneca; hereafter ChAdOx1) SARS-CoV-2 vaccines. Post-booster tests were offered to participants who were . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 15, 2022. ;  https://doi.org/10.1101/2022.02.14.22270930 doi: medRxiv preprint seronegative after their primary course of vaccination. We utilised an assay with proven sensitivity for detection of combined IgG, IgA and IgM antibodies to the SARS-CoV-2 spike antigen 21 that has been validated as a correlate of protection against breakthrough COVID-19 in two populations. 22, 23 Methods

COVIDENCE UK is a prospective, longitudinal, population-based observational study of COVID-19 in the UK population (www.qmul.ac.uk/covidence). 20 Inclusion criteria were age ≥16 years and UK residence at enrolment, with no exclusion criteria.

Participants were invited via a national media campaign to complete an online baseline questionnaire to capture information on potential symptoms of COVID-19 experienced since February 1, 2020; results of any COVID-19 tests; and details of a wide range of potential risk factors for COVID-19 and determinants of vaccine response (Table S1, Supplementary Appendix). Online monthly follow-up questionnaires captured incident test-confirmed COVID-19 and vaccination details (Table S2, Supplementary Appendix), and a pre-vaccination serology study was conducted to evaluate risk factors for SARS-CoV-2 infection. 24 The study was launched on May 1, 2020, and closed to enrolment on October 6, 2021. Participants in the cohort were invited via email to participate in post-vaccination antibody studies and to give additional consent for these. The primary analysis presented here includes data from all participants for whom a serology result was available following administration of two doses of ChAdOx1 or BNT162b2; an additional antibody test following administration of a third booster dose of vaccine was offered to all participants who were seronegative after two vaccine doses, and a randomly selected subset of positive controls who were seropositive after two vaccine doses. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 15, 2022 (≥1) or negative (<1). Dried blood spot eluates were pre-diluted 1:40 with 0.05% PBS-Tween using a Dynex Revelation automated absorbance microplate reader (Dynex Technologies; Chantilly, VA, USA). Plates were developed after 10 min using 3,3′,5,5′tetramethylbenzidine core, and orthophosphoric acid used as a stop solution (both TBS). Optical densities at 450 nm were measured using the Dynex Revelation.

Study outcomes were presence vs absence of antibodies against SARS-CoV-2 (analysed as a binary outcome) and antibody titres (continuous outcome restricted to the individuals who were seropositive after receiving two vaccine doses).

Sixty-six putative determinants of post-vaccination serological responses were selected a priori, covering vaccination type and timing, sociodemographic, occupational, and lifestyle factors; longstanding medical conditions and prescribed medication use; Bacille Calmette Guérin (BCG) vaccine status, and diet and supplemental micronutrient intake (Tables S1-2, Supplementary Appendix). These factors, which were obtained from the baseline or monthly questionnaires, were included as independent variables in our models. To produce participant-level covariates for each class of medications investigated, questionnaire responses were mapped to drug classes listed in the British National Formulary (BNF) or the DrugBank is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.14.22270930 doi: medRxiv preprint and Electronic Medicines Compendium databases if not explicitly listed in the BNF, as previously described. 20 Index of Multiple Deprivation (IMD) 2019 scores were assigned according to participants' postcodes, and categorised into quartiles.

Full details of the sample size calculation and statistical analysis are provided in Supplementary Material. Briefly, logistic regression models were used to estimate adjusted ORs, 95% (CIs) and associated pairwise P-values for potential determinants of post-vaccination seronegativity in all participants. Linear regression models were used to estimate beta-coefficients, 95% CIs and associated pairwise P-values for potential determinants of log-transformed antibody titres in the subset of seropositive participants. For ease of interpretation, log-transformed estimates of antibody titres were exponentiated and a percentage increase or decrease was calculated for every one-unit increase in the potential determinant. We first estimated ORs and betacoefficients in minimally adjusted models, and included factors independently associated with each outcome at the 10% significance level in fully adjusted models.

In a sensitivity analysis, we excluded participants from the analysis of antibody titres after two vaccine doses who reported a positive RT-PCR or lateral flow test for SARS-CoV-2 between the date of their second dose of vaccine and the date on which they provided their dried blood spot sample. We also stratified the analysis of antibody titres following two vaccine doses according to the type of vaccine received to explore whether determinants of antibody responses to two vaccine doses were consistent for ChAdOx1 vs BNT162b2. Given reports that peri-vaccination use of antipyretic analgesics may attenuate vaccine immunogenicity, 26 we also conducted an exploratory analysis to determine the influence of taking paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) to treat post-vaccination symptoms on postvaccination antibody titres.

The study funders had no role in the study design, data analysis, data interpretation, or writing of the report. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.14.22270930 doi: medRxiv preprint

A total of 15,527 participants were invited to participate in the study of antibody responses following two vaccine doses, of whom 13,005 consented to take part.

Serology results were available for 9,244 participants, of whom 9,101 received two doses of ChAdOx1 (n=5,770) or BNT162b2 (n=3,331) for their primary vaccination course and were included in this analysis ( Figure S1 , Supplementary Appendix). Their characteristics are presented in Table   S3 : 261 received a BNT162b2 booster (221 after two doses of ChAdOx1 and 40 after two doses of BNT162b2) and 43 received a mRNA-1273 (Moderna) booster (all after two doses of ChAdOx1). Table 2 presents results of minimally adjusted and multivariable analyses to identify factors that were independently associated with the absence of detectable anti-spike IgG/A/M following two doses of ChAdOx1 or BNT162b2. After adjusting for age and sex, 32 independent variables associated with post-vaccination serostatus with P<0.10 and were fitted in a fully adjusted model. Ten factors in the fully adjusted model is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

To identify factors influencing the magnitude of antibody responses to COVID-19 vaccination, we investigated determinants of SARS-CoV-2 antibody titres in the subset of 8,727 participants who were seropositive following their second COVID-19 vaccine dose. Results of this analysis are presented in Table 3 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint pre-vaccination vs those who were seronegative pre-vaccination, and 117.9% higher, 105.6-130.9, for individuals who were seropositive with COVID-19 symptoms prevaccination vs those who were seronegative pre-vaccination). All the above determinants of post-vaccination antibody titres remained significant (P<0.05) when we performed a sensitivity analysis excluding 23 individuals who reported RT-PCR-or lateral flow test-confirmed SARS-CoV-2 infection after their second vaccine dose, but before their serology sampling date (data not shown).

To explore whether determinants of antibody responses to vaccination were consistent is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.14.22270930 doi: medRxiv preprint hypertension (Pinteraction=0.035), regular consumption of selenium supplements (Pinteraction=0.021) and use of systemic immunosuppressant medication (Pinteraction=0.046; Figure S2 , Supplementary Appendix).

Results of an exploratory analysis to determine the influence of taking paracetamol or NSAIDs to treat post-vaccination symptoms are presented in Table S6 . After fitting post-vaccination paracetamol/NSAID use into the main multivariable model we found a significant positive association between this factor and post-vaccination antibody titres. We then reasoned that this association could be confounded by an association between presence or severity of post-vaccination symptoms and higher postvaccination antibody titres. After additionally correcting for report of post-vaccination symptoms (i.e., headache, fever, local soreness), the association between postvaccination paracetamol/NSAID use and post-vaccination titres was rendered statistically non-significant.

Anti-spike Ig GAM titres for the subset of participants who provided dried blood spot samples following administration of a third vaccine dose are presented in Figure 2 . Of 247 participants who had undetectable anti-spike IgGAM following two vaccine doses, all but eight (3.2%) had detectable antibodies following subsequent administration of a single booster dose. Details of the vaccine regimens, medical history and medication for the eight participants who remained seronegative following their booster dose are presented in Table S7 , Supplementary Material: seven were taking immunosuppressant medication (five for autoimmune disease, two following solid organ transplant) and one had a primary antibody deficiency. Median post-booster antibody titres were higher among participants who were seropositive vs seronegative after two vaccine doses. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.14.22270930 doi: medRxiv preprint

We present results of a large population-based study examining a comprehensive range of potential determinants of combined IgG, IgA and IgM responses to two very widely used SARS-CoV-2 vaccines. A major finding was that 5.8% of participants did is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.14.22270930 doi: medRxiv preprint booster dose of BNT162b2 or mRNA-1273 provides strong support for roll-out of third vaccine doses to achieve near-universal seroconversion in the general population.

Our results with respect to the adverse influence of older age, shorter inter-dose interval, poorer general health, immunodeficiency and immunosuppressants on postvaccination antibody responses are also broadly consistent with those of others 4-9as is the finding that pre-vaccination SARS-CoV-2 infection associates with higher antibody titres after vaccination. 9, 12, 13 However, we also report a number of novel findings. The independent association between regular use of vitamin D supplements and reduced risk of post-vaccination seronegativity echoes results of a previous study where we showed that high-dose vitamin D replacement enhances antigen-specific cellular responses following vaccination against varicella zoster virus; 29 an intervention study nested within a randomised controlled trial of vitamin D supplementation for prevention of COVID-19 (ClinicalTrials.gov identifier NCT04579640) is currently ongoing to explore this finding further. Associations between increased risk of postvaccination seronegativity and use of sodium-glucose co-transporter-2 (SGLT2) inhibitors or anti-platelet drugs have also not previously been reported to our knowledge. Both drug classes are recognised to have immunomodulatory actions, 30, 31 but further studies are needed to determine whether the associations we report can be replicated in other cohorts.

We also found that White ethnicity and lower BMI both associated with lower postvaccination antibody titres, independently of pre-vaccination SARS-CoV-2 serostatus.

Ethnic variation in SARS-CoV-2 vaccine immunogenicity has not been widely studied to date: one study has reported lower antibody responses to vaccination in Jewish vs non-Jewish health care workers in Israel, 9 while a population-based UK study reported higher antibody titres in 'non-Whites' vs Whites. However, pre-vaccination serostatus was not available for all participants in these studies; this omission is potentially important, because unvaccinated people of South Asian ethnic origin were at higher risk of SARS-CoV-2 infection in the pre-vaccination era. 20, 24 We demonstrate for the first time that higher anti-spike titres among vaccinated people of South Asian origin are not attributable to the higher rates of pre-vaccination SARS-CoV-2 infection that we have previously reported. 20,24 The reasons for this phenomenon require further investigation: ethnic variation in recognition of SARS-CoV-2 T cell epitopes is recognised, 32 and it may be that analogous variation in B cell epitopes underlies the is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.14.22270930 doi: medRxiv preprint ethnic differences in antibody responses to vaccination seen here. By contrast with ethnicity, several studies have investigated the impact of BMI on post-vaccination antibody titres. Their results are inconsistent, with one reporting lower antibody responses in those with BMI >30 kg/m 2 , 4 another reporting higher responses in those with higher BMI 33 and two reporting no association. 34, 35 Of note, studies investigating antibody responses to influenza vaccination report higher titres initially in obese participants, but a greater decline thereafter. 36 This finding highlights the importance of longer term follow-up to elucidate the influence of BMI on humoral responses to vaccination.

We also report some important null results. The lack of association between time of day of vaccination and degree of antibody response conflicts with findings of studies which variously report higher anti-spike responses in those vaccinated earlier 37 or later 38 in the day. We also show no association between pre-or post-vaccination use of paracetamol or NSAIDs and antibody responses, after adjustment for incidence of post-vaccination symptoms. This provides reassurance that use of these medications to manage reactive post-vaccination symptoms does not compromise SARS-CoV-2 vaccine immunogenicity. We also show no association between higher titres and socioeconomic deprivation, as reported by others; 4,7 this may reflect the fact that other studies did not adjust for pre-vaccination serostatus, which is more likely to be positive in socioeconomically deprived populations. There was no evidence of association for lifestyle factors hypothesised to influence vaccine responses including dietary factors, use of micronutrient supplements other than vitamin D, sleep, alcohol use and tobacco smoking.

Our study has several strengths. We utilised a CE-marked assay with high sensitivity and specificity that targets three different types of antibody, 21 and that we have is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.14.22270930 doi: medRxiv preprint immunogenicity, and to adjust for multiple confounders, including pre-vaccination serostatus.

Our study also has some limitations. We did not study cellular responses to vaccination, and these may be discordant with humoral responses. 10, 27 We also studied responses at an early time point only; a high early peak in antibody titres following vaccination is not necessarily an indicator of durable response. 36 As with any observational study, we cannot exclude the possibility that some of the associations we report might be explained by residual or unmeasured confounding. However, we is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.14.22270930 doi: medRxiv preprint approval of the version to be published, and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work were appropriately investigated and resolved. DAJ, MT, HH, GV and FT had full access to all data in the study, and ARM had final responsibility for the decision to submit for publication. 

De-identified participant data will be made available upon reasonable request to the corresponding author, subject to terms of Research Ethics Committee approval and Sponsor requirements.

This study was supported by a grant from Barts Charity to ARM and CJG (MGU0466) and by donations to Queen Mary University of London from the Fischer Family Trust, is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.14.22270930 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.14.22270930 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.14.22270930 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.14.22270930 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.14.22270930 doi: medRxiv preprint

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Heterogeneous Longitudinal Antibody Responses to Covid-19 mRNA Vaccination

Factors That Influence the Immune Response to Vaccination

Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine

Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England

Effectiveness of mRNA BNT162b2 Vaccine 6 Months after Vaccination among Patients in Large Health Maintenance Organization

Serological Response to SARS-CoV-2 Messenger RNA Vaccine: Real-World Evidence from Italian Adult Population

Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: realworld evidence from healthcare workers

Discordance Between SARS-CoV-2-specific Cell-mediated and Antibody Responses Elicited by mRNA-1273 Vaccine in Kidney and Liver Transplant Recipients

Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals

Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status

Morning vaccination enhances antibody response over afternoon vaccination: A cluster-randomised trial

Optimising COVID-19 vaccine efficacy by ensuring nutritional adequacy

Could a good night's sleep improve COVID-19 vaccine efficacy?

COVID-19 pandemic and alcohol consumption: Impacts and interconnections

Does smoking have an impact on the immunological response to COVID-19 vaccines? Evidence from the VASCO study and need for further studies

Abbreviations: IQR, inter-quartile range; CI, confidence interval

BMI, body mass index

Ig, immunoglobulin ; IMD, index of multiple deprivation

chronic obstructive pulmonary disease; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; COVID-19, coronavirus disease

H2, histamine 2; SSRI, selective serotonin reuptake inhibitor

SGLT2, sodium-glucose cotransporter-2

Adjusted for age, sex, vaccine type, time from second dose to sampling, inter-dose interval, time of second vaccination, quarter of second vaccination, ethnicity, BMI, educational level, alcohol intake, light exercise, vigorous exercise, sleep, selfassessed general health, hypertension, pre-vaccination SARS-CoV-2 status and pre-vaccination use of vitamin C supplements, omega-3 fatty acid supplements, SSRI antidepressants, thiazide diuretics and metformin(3) Heart disease defined as coronary artery disease or heart failure

Immunodeficiency defined as HIV, primary immune deficiency or other immunodeficiency

Major neurological conditions defined as stroke, transient ischaemic attack, dementia, Parkinson's disease, multiple sclerosis or motor neurone disease